Why Read “The Gold Sheet”?
“The Gold Sheet" delivers expert intel and analysis of developments in FDA regulations and policies governing the manufacture and processing of healthcare products; state-of-the-art production and quality techniques; trends in quality control practices around the globe; best practices in supply chain integrity; and a vast range of GMP issues, such as sterility, microbial controls, validation, laboratory data integrity, cross-contamination, out-of-spec (OOS) results and stability testing. “The Gold Sheet" is widely known for its user-friendly tables of drug recall and warning letter data, early warning of new directions in FDA enforcement policy, and insights from peers on ensuring quality from contract suppliers and service providers.
Who Reads “The Gold Sheet”?
Top regulatory affairs executives and other biopharma industry professionals in quality control, along with consultants, suppliers and industry attorneys, turn to "The Gold Sheet" to gain a better understanding of FDA regulations, insight into improving compliance and reducing costs, and analysis of trends in recalls and warning letters; and to help them improve their supply chain, adopt new best practices, avoid disastrous inspection results, and control manufacturing processes in an increasingly unpredictable environment.
Subscription Terms
Subscription Options
Buy Now
Includes:
Email newsletter with latest headlines, breaking news alerts, and access to “The Gold Sheet” — insightful analysis to help you comply with U.S. and international pharmaceutical manufacturing QA/QC requirements.
Multiple users/site features: Contact Deanna Flanick at +1-908-547-2141 or D.Flanick@Elsevier.com.